AbbVie
ABBV
$209.41
-0.47%
AbbVie is a global pharmaceutical company focused on developing and commercializing therapies across immunology, oncology, neuroscience, and aesthetics. It is a market leader in immunology with blockbuster drugs Skyrizi and Rinvoq, and has established a significant presence in oncology and medical aesthetics through strategic acquisitions like Allergan, Cerevel, and ImmunoGen. The current investor narrative centers on the company's successful transition beyond Humira's patent cliff, with robust growth from its immunology portfolio and recent pipeline advancements in obesity and neuroscience, though recent news highlights competitive pressures and a manufacturing-related FDA delay for an aesthetics product.…
ABBV
AbbVie
$209.41
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating & Thesis: Hold. AbbVie is a fundamentally strong company navigating a successful portfolio transition, but its stock is fairly valued at current levels with near-term headwinds capping upside. The bullish analyst consensus and 12.96x forward P/E are balanced by significant technical weakness and competitive risks.
Supporting Evidence: The primary valuation metric, the forward P/E of 12.96x, is reasonable for a large-cap pharma and implies significant earnings growth from the $1.02 quarterly EPS. Revenue growth is solid at 10.04% YoY, and profitability is robust with a Q4 gross margin of 84.02% and $18.70 billion in TTM FCF. However, the stock trades at a premium Price/Sales ratio of 6.65x and has dramatically underperformed the market (-19.47% vs. SPY over 6 months), reflecting investor caution.
Risks & Conditions: The two biggest risks are valuation compression if forward earnings disappoint and market share erosion from new competitive products. This Hold would upgrade to a Buy if the stock breaks below $200 (offering a greater margin of safety) and shows sustained technical recovery above $230, or if Q1 2026 earnings convincingly demonstrate the $20+ EPS run-rate. It would downgrade to Sell if revenue growth decelerates below 5% YoY or if the forward P/E expands above 15x without corresponding earnings upgrades. The stock is currently fairly valued relative to its forward earnings potential but carries a premium on sales-based metrics.
Sign up to view all
ABBV 12-Month Price Forecast
AbbVie presents a classic 'show me' story. The fundamentals of cash flow and immunology growth are strong, but the stock's technical breakdown and high trailing valuation require proof that earnings can normalize at the $20+ level. The base case of range-bound trading is most likely, as investors await confirmation of sustained post-Humira profitability. The stance would upgrade to bullish on a conclusive earnings beat that validates the forward multiple, or on a technical breakout above $240. It would turn bearish if quarterly revenue growth decelerates into the mid-single digits or if pipeline setbacks emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $272.23 and implied upside of +30.0% versus the current price.
Average Target
$272.23
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$168 - $272
Analyst target range
Analyst coverage is robust with 11 firms providing estimates, and recent institutional ratings show a generally bullish sentiment with actions like 'Overweight', 'Buy', and 'Outperform' from major firms including Morgan Stanley and Piper Sandler. The consensus recommendation is bullish, with an average EPS estimate of $20.20 for the coming year, implying significant earnings growth from the current depressed level. The target price range is not explicitly provided in the data, but the wide dispersion in estimated EPS (low of $19.56 to high of $20.57) suggests moderate uncertainty around the precise earnings trajectory. The pattern of recent ratings shows stability, with most firms reiterating their positive stances in early 2026, indicating sustained conviction in the company's long-term story despite near-term stock price weakness.
Bulls vs Bears: ABBV Investment Factors
The bull case for AbbVie is anchored in its successful business model transition, with Skyrizi and Rinvoq driving robust growth, exceptional cash generation supporting shareholder returns, and a compelling forward valuation. The bear case focuses on the stock's recent technical breakdown, elevated trailing valuation multiples that demand perfect execution, and emerging competitive/regulatory headwinds. Currently, the bearish evidence holds more weight in the near term, as the stock's significant underperformance and high trailing P/E reflect market skepticism despite strong fundamentals. The single most important tension is whether the company's forward P/E of 12.96x—implying massive earnings normalization—is justified, or if competitive pressures and execution missteps will prevent this earnings recovery, triggering further multiple compression.
Bullish
- Strong Immunology Growth Offsets Humira: Skyrizi and Rinvoq generated $7.38 billion in segment revenue, driving a 10.04% YoY revenue increase in Q4 2025 to $16.62 billion. This demonstrates successful execution of the post-Humira transition, with the immunology portfolio now the primary growth engine.
- Exceptional Profitability and Cash Flow: Q4 2025 gross margin spiked to 84.02%, and the company generated $18.70 billion in trailing twelve-month free cash flow. This robust cash generation provides ample liquidity to fund the dividend, strategic acquisitions, and debt repayment.
- Attractive Forward Valuation: The forward P/E of 12.96x, based on analyst consensus EPS of $20.20, represents a significant discount to the elevated trailing P/E of 96.26x. This suggests the market has priced in a substantial earnings recovery, offering a compelling entry point if achieved.
- Analyst Conviction and Pipeline Catalysts: Analyst sentiment is bullish with 11 firms covering and recent 'Overweight' and 'Buy' ratings. Positive pipeline developments, including up to 10% weight loss in early obesity drug data and strong Skyrizi Crohn's results, provide future growth catalysts.
Bearish
- Elevated Trailing P/E and Valuation Risk: The trailing P/E of 96.26x is a substantial premium to sector averages and reflects peak earnings expectations. This leaves little room for disappointment and creates significant valuation compression risk if forward earnings fail to materialize.
- Recent Technical Downtrend and Underperformance: The stock is down 9.46% over the past 6 months and underperformed the SPY by 17.54% over the past 3 months. Trading at 86% of its 52-week range near $210, it shows weak momentum and a lack of near-term bullish catalysts.
- Balance Sheet Leverage and Liquidity Constraint: The debt-to-equity ratio is a negative -21.12 due to negative shareholder equity, and the current ratio is a concerning 0.67. While strong FCF mitigates this, it indicates a leveraged balance sheet with potential short-term liquidity pressure.
- Intensifying Competitive and Regulatory Pressures: Recent news highlights an FDA rejection for a wrinkle drug due to manufacturing issues and new competition from Johnson & Johnson's oral psoriasis drug. These events introduce near-term execution risks and threaten long-term market share.
ABBV Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of +15.80% but a 6-month decline of -9.46%, indicating a significant recent pullback. Trading at $210.39, the price sits at approximately 86% of its 52-week range ($180.25 to $244.81), suggesting it is closer to the lower bound and may represent a value opportunity after a substantial drawdown. Recent momentum is weak and diverges from the longer-term positive yearly trend; the stock is down -9.12% over the past 3 months and up only +0.95% over the past month, signaling deceleration and potential consolidation near recent lows. This divergence, coupled with a 1-month relative strength of -4.65 against the SPY, indicates significant underperformance and a lack of bullish catalysts in the near term. Key technical support is the 52-week low of $180.25, while resistance lies near the 52-week high of $244.81; a breakdown below support would signal a continuation of the downtrend, whereas a recovery above $230 could suggest a reversal. The stock's beta of 0.305 indicates it is approximately 70% less volatile than the broader market, which, combined with a max drawdown of -19.23%, suggests it has been a relatively defensive holding during recent market weakness.
Beta
0.30
0.30x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$180-$245
Price range past year
Annual Return
+13.8%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +0.5% | +4.0% |
| 3m | -10.1% | +8.2% |
| 6m | -10.1% | +11.5% |
| 1y | +13.8% | +24.3% |
| ytd | -8.7% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue growth is solid but shows some quarterly volatility; Q4 2025 revenue was $16.62 billion, representing a 10.04% year-over-year increase, though this follows a weaker Q3 2025 where revenue was $15.78 billion. The immunology portfolio, led by Skyrizi ($5.01 billion segment revenue) and Rinvoq ($2.37 billion), is the primary growth driver, significantly offsetting the decline of Humira ($1.25 billion). Profitability is strong but impacted by one-time items; Q4 2025 net income was $1.82 billion with a net margin of 10.93%, and the gross margin was an exceptional 84.02%, though this spiked from 66.38% in Q3 due to a significant reduction in cost of revenue. The full-year picture shows a return to robust profitability after a net loss in Q4 2024, with operating cash flow consistently strong. The balance sheet is leveraged but cash-generative; the debt-to-equity ratio is a negative -21.12 due to negative shareholder equity, but the company generated $18.70 billion in trailing twelve-month free cash flow, providing ample liquidity to fund dividends, acquisitions, and debt repayment. The current ratio of 0.67 indicates potential short-term liquidity constraints, but substantial FCF mitigates this concern.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given the positive net income of $1.82 billion in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 96.26x, while the forward P/E is a much lower 12.96x, indicating the market expects a significant earnings recovery and normalization in the coming year. Compared to sector averages, AbbVie's trailing P/E of 96.26x is a substantial premium, though its forward P/E of 12.96x would represent a discount if earnings materialize as forecast; its Price/Sales ratio of 6.65x and EV/Sales of 6.94x are more in line with large-cap pharma peers. Historically, the stock's own trailing P/E of 96.26x is near the top of its multi-year range, which has seen figures from the teens to over 3,500 during loss-making quarters; this high current multiple reflects the market's anticipation of future earnings growth but also leaves little room for disappointment.
PE
96.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -3572x~551x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's balance sheet shows significant leverage, with a debt-to-equity ratio of -21.12 and a weak current ratio of 0.67, indicating potential short-term liquidity constraints despite $18.70 billion in TTM FCF. Earnings have been highly volatile, swinging from a net loss in Q4 2024 to a $1.82 billion profit in Q4 2025, with gross margins spiking to 84.02% from 66.38% the prior quarter, raising questions about sustainability. Revenue, while growing at 10.04% YoY, remains concentrated in the immunology portfolio (Skyrizi and Rinvoq), creating dependency on these blockbusters to offset Humira's decline and fend off new competitors like J&J's recently approved psoriasis drug.
Market & Competitive Risks: The stock trades at a trailing P/E of 96.26x, a substantial premium to sector averages, creating high valuation compression risk if forward EPS of $20.20 fails to materialize. Recent news highlights direct competitive threats, including an FDA-approved oral competitor to Skyrizi and an FDA rejection for an aesthetics product due to manufacturing issues. While the beta of 0.305 suggests low market correlation, the stock's 19.23% max drawdown and persistent underperformance (-17.54% vs. SPY over 3 months) indicate it faces unique, company-specific headwinds beyond broader market movements.
Worst-Case Scenario: The most damaging scenario involves a combination of competitive setbacks and earnings disappointment. Specifically, faster-than-expected market share loss for Skyrizi/Rinvoq to new oral therapies, coupled with a failure to achieve the consensus $20.20 EPS, would shatter the forward earnings narrative. This could trigger analyst downgrades and multiple compression toward the sector median. Realistic downside could see the stock re-testing its 52-week low of $180.25, representing a potential loss of approximately -14% from the current price of $210.39. A breach of this support could lead to a further decline toward the $170-$175 range, amplifying losses to -17% to -19%.
FAQ
The key risks are, in order of severity: 1) Valuation & Execution Risk: The high trailing P/E of 96.26x leaves no room for error; failure to achieve forward EPS targets could cause a sharp multiple contraction. 2) Competitive Risk: New drug approvals, like J&J's oral psoriasis treatment, directly threaten the growth of blockbusters Skyrizi and Rinvoq. 3) Financial Risk: The balance sheet is leveraged (debt-to-equity of -21.12) with a weak current ratio of 0.67, though strong cash flow mitigates this. 4) Regulatory/Operational Risk: Recent FDA rejection for a manufacturing issue demonstrates vulnerability in the aesthetics segment.
The 12-month forecast presents three scenarios. The base case (50% probability) sees the stock trading between $220 and $240 as it meets analyst EPS consensus of ~$20.20. The bull case (30% probability) targets $244 to $260, driven by earnings beats and pipeline successes. The bear case (20% probability) warns of a drop to $180-$200 if competition intensifies and earnings disappoint. The most likely outcome is the base case of range-bound trading, as the market requires concrete evidence that the company's earnings have sustainably recovered from the Humira patent cliff.
ABBV's valuation is a tale of two multiples. It appears significantly overvalued based on its trailing P/E of 96.26x, which is a major premium to the sector. However, it appears fairly valued to slightly undervalued based on its forward P/E of 12.96x, which is in line with or below many large-cap pharma peers. This dichotomy shows the market is pricing in a massive earnings recovery. The Price/Sales ratio of 6.65x is at a premium, reflecting its high-margin profile. Overall, the stock is fairly valued relative to its forward earnings potential but carries little margin of safety if those estimates are missed.
ABBV is a good buy for patient, income-focused investors with a long-term horizon, but less attractive for short-term traders. The forward P/E of 12.96x offers reasonable value if the company hits its $20.20 EPS target, implying potential upside. However, the stock's recent 9.46% six-month decline and significant underperformance versus the market highlight near-term headwinds. The biggest risk is valuation compression if earnings disappoint. It is a good buy for those who believe in the sustainability of immunology growth and can tolerate potential further volatility.
ABBV is unequivocally more suitable for a long-term investment horizon. Its low beta of 0.305 and reliable 2.87% dividend yield make it a stable holding for portfolios seeking income and lower volatility. The investment thesis revolves around the multi-year growth of the immunology portfolio and pipeline development, which are not short-term stories. Given the recent technical weakness and 'show me' phase regarding earnings, short-term trading is fraught with uncertainty. A minimum holding period of 2-3 years is recommended to allow the post-Humira transition story to fully play out and for competitive threats to be properly assessed.
